Iovance Biotherapeutics, Inc.
IOVAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeIovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic. At a $6.38B market cap, Iovance Biotherapeutics, Inc. ranks as a mid-cap company within healthcare. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Market Cap
$6.38B
Beta
0.76
P/E (TTM)
—
P/E (Fwd)
-71.98
EPS (TTM)
$-0.69
EPS (Fwd)
$-0.20
ROE
-40.4%
ROA
-20.3%
Cash
$297.7M
Total Debt
$46.0M
Free CF
-$187.8M
52W Change
510.0%
Annual Financials
Cash vs Debt
Where IOVA stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, IOVA finished 125.50% above its 150-day moving average ($6.04) and 156.98% above its 200-day moving average ($5.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IOVA overbought or oversold?
At the October 19, 2026 close, IOVA's RSI(14) was 63.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Iovance Biotherapeutics, Inc. holds $297.7M in cash against $46.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$187.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -40.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Iovance Biotherapeutics, Inc.'s trajectory.